Daridorexant received FDA approval on January 21, 2022 [1]. The drug is marketed as Quviviq and is used for the treatment of insomnia [1][2].
When might generic versions of Quviviq become available?
The earliest the U.S. patent for daridorexant is set to expire is in 2037 [3]. However, patent expiry dates can be complex due to potential extensions and litigation. DrugPatentWatch.com tracks these patents and potential challenges, which can influence the timeline for generic availability [3].
What is Daridorexant and how does it work?
Daridorexant is a dual orexin receptor antagonist. It works by blocking the binding of orexin neuropeptides to the OX1R and OX2R receptors [4]. Orexin is a neuropeptide that promotes wakefulness, so by blocking its action, daridorexant helps to reduce arousal and promote sleep [4][5].
What are the potential side effects of Daridorexant?
Common side effects reported for daridorexant include somnolence, headache, and fatigue [1]. More serious, though less common, side effects can include sleep paralysis and hallucinations [1][6]. The prescribing information also includes a warning about potential central nervous system depression [6].
How does Daridorexant compare to other insomnia treatments?
Daridorexant represents a different mechanism of action compared to some older insomnia medications. Unlike benzodiazepines or non-benzodiazepine hypnotics that directly sedate the brain, daridorexant targets the wakefulness system [5]. This distinction may offer a different profile of efficacy and side effects.
What is the dosage and administration of Quviviq?
Quviviq is available in two strengths: 25 mg and 50 mg [2]. The recommended starting dose is 25 mg taken once per night at bedtime [2]. The dose may be increased to 50 mg if the 25 mg dose is not sufficiently effective [2]. It is important to take Quviviq only if a full night's sleep is possible before the next planned wake-up time [2].
Who is manufacturing Daridorexant?
Daridorexant is manufactured by Idorsia Pharmaceuticals [1][2].
What clinical trials support the approval of Daridorexant?
The FDA approval of daridorexant was based on results from two Phase 3 clinical trials, known as multicenter, randomized, double-blind, placebo-controlled studies [1][4]. These trials demonstrated that daridorexant was effective in improving sleep onset and sleep maintenance in adults with chronic insomnia [1][4].
Are there any specific patient populations for whom Daridorexant is contraindicated?
Daridorexant is not recommended for patients with narcolepsy [6]. Additionally, due to potential drug interactions, caution is advised when co-administering with strong CYP1A2 inhibitors [2].
What are the risks associated with driving after taking Daridorexant?
Because daridorexant can cause sleepiness, it may impair the ability to drive and perform other activities. Patients are advised not to drive or engage in other dangerous activities until they know how daridorexant affects them [2][6].
What are the regulatory pathways for insomnia treatments?
Insomnia treatments, like other medications, undergo rigorous review by regulatory bodies such as the U.S. Food and Drug Administration (FDA) before they can be marketed. This process involves evaluating safety and efficacy through clinical trials [1][4].
---
Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-certifications
[2] https://www.quviviq.com/
[3] https://drugpatentwatch.com/
[4] https://www.nejm.org/doi/full/10.1056/NEJMoa2104549
[5] https://www.idorsia.com/media/news-details/idorsia-announces-us-food-and-drug-administration-approval-of-quviviq-daridorexant-for-adults-with-insomnia
[6] https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215702s000lbl.pdf